Endokarditis – ein Update

Zusammenfassung

Die Endokarditis stellt weiterhin eine diagnostische und therapeutische Herausforderung dar. Der Artikel gibt ein Update zum aktuellen Management und der Prophylaxe der Endokarditis. Die Empfehlungen der überarbeiteten Leitlinien der European Society of Cardiology und der American Heart Association werden verglichen und diskutiert. Die neue Entität Transkatheter-Aortenklappen-Implantation (TAVI)-assoziierte Endokarditis wird vorgestellt.

Abstract

Infective endocarditis remains a diagnostic and therapeutic challenge. This update focuses on recent developments in the diagnostic workup, therapeutic management and prophylaxis of infective endocarditis. Recommendations of the new guidelines of the European Society of Cardiology and the updated statement of the American Heart Association are compared and discussed. The new entity transcatheter aortic valve implantation (TAVI)-associated endocarditis is also highlighted.

• Literatur

• 1 Tanis W, Teske AJ, van Herwerden LA et al. The additional value of three-dimensional transesophageal echocardiography in complex aortic prosthetic heart valve endocarditis. Echocardiography 2015; 32: 114-125
• 2 Saby L, Laas O, Habib G et al. Positron emission tomography / computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 2013; 61: 2374-2382
• 3 Habib G, Lancellotti P, Antunes MJ et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;
• 4 Baddour LM, Wilson WR, Bayer AS et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132: 1435-1486
• 5 Casalta JP, Zaratzian C, Hubert S et al. Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim / sulfamethoxazole and clindamycin-Preliminary report. Int J Antimicrob Agents 2013; 42: 190-191
• 6 Bai AD, Showler A, Burry L et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. J Antimicrob Chemother 2015; 70: 1539-1346
• 7 Nannini EC, Singh KV, Arias CA, Murray BE. In vivo effect of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible Staphylococcus aureus strain showing an inoculum effect against cefazolin. Antimicrob Agents Chemother 2013;
• 8 Carugati M, Bayer AS, Miro JM et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrob Agents Chemother 2013; 57: 6213-6222
• 9 Moore CL, Osaki-Kiyan P, Haque NZ et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54: 51-58
• 10 Murray KP, Zhao JJ, Davis SL et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration > 1 mg / L: a matched cohort study. Clin Infect Dis 2013; 56: 1562-1569
• 11 Paul M, Bronstein E, Yahav D et al. External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA. BMJ Open 2015; 5: e008838
• 12 Paul M, Bishara J, Yahav D et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015; 350: h2219
• 13 Pericas JM, Llopis J, Cervera C et al. Infective endocarditis in patients with an implanted transcatheter aortic valve: Clinical characteristics and outcome of a new entity. J Infect 2015; 70: 565-576
• 14 Latib A, Naim C, De Bonis M et al. TAVR-associated prosthetic valve infective endocarditis: results of a large, multicenter registry. J Am Coll Cardiol 2014; 64: 2176-2178
• 15 Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-e434
• 16 Richey R, Wray D, Stokes T. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ 2008; 336: 770-771
• 17 Dayer MJ, Jones S, Prendergast B et al. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. Lancet 2015; 385: 1219-1228